As previously reported, Sarah Romano resigned as Chief Financial Officer of Kiora Pharmaceuticals, Inc. effective as of February 25, 2022 (the Effective Date) to pursue another opportunity. Following Ms. Romano's resignation, the Company appointed Michael Meluzio, CPA, the Corporate Controller of the Company, as the Company's principal financial officer and principal accounting officer, effective as of the Effective Date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5328 USD | -1.33% | +3.46% | +1.99% |
05-10 | Earnings Flash (KPRX) KIORA PHARMACEUTICALS Posts Q1 Revenue $16M | MT |
03-25 | Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.99% | 14.18M | |
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
+31.84% | 12.13B |
- Stock Market
- Equities
- KPRX Stock
- News Kiora Pharmaceuticals, Inc.
- Kiora Pharmaceuticals, Inc. Appoints Michael Meluzio as Principal Financial Officer and Principal Accounting Officer